Deal of the Day — limited-time pharmacy picks!
Sovihep V Tablet

Sovihep V Tablet

Prescription requiredRx Required

Salt Composition: Sofosbuvir 400mg + Velpatasvir 100mg

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

28 tablet

About The Product

Hepatitis C

Sovihep V tablet is a combination of two antiviral drugs, Sofosbuvir and Velpatasvir. This medicine is used in the treatment of chronic Hepatitis C virus (HCV). Store this medicine at room temperature and keep it away from light and moisture. Chronic hepatitis C virus infection is the term used when the infection progresses into a stage that lasts for a long time. By stopping the hepatitis C virus from proliferating within your body, Sovihep V Tablet helps lower its number. This helps in infection control and speeds up your recovery. You must take this medication exactly as directed by your doctor, using the recommended dosage.

Uses

Chronic hepatitis C virus (HCV) infection

Side Effects

  • Sovihep V tablet may cause some serious and unwanted side effects that require immediate medical attention; otherwise, it can also lead to a higher risk.
  • Do not forget to discuss the risks and benefits of this medication with your doctor.​ Headache Diarrhea Nausea Difficulty in breathing Cough and chills Loss of appetite Muscle pain Irregular heartbeat Anemia

Dosage and Administration

  • Take this medicine as prescribed by your doctor.
  • Do not skip or miss your dosing schedule.
  • This medicine can be taken with or without food.
  • In case of an overdose, the doctor will provide emergency medical treatment.

Mechanism of action

Sovihep V works by blocking different steps in the reproduction of viruses. Sofosbuvir with Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A replication complex inhibitor.

Sofosbuvir is approved for the treatment of genotype 1, 2, 3, and 4 HCV infection with different regimens and durations depending on the HCV genotype. After the oral administration, the effect of this medicine can be observed in 2 to 4 hours.

Safety Advice

Alcohol
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
Do not take Sovihep V tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
Do not take Sovihep V tablet without a doctor's consultation in case of kidney problems.
Liver
Share your medical history with the doctor in case of liver disease before taking this medicine.

Missed Doses

  • It is advisable not to miss a dose of Sovihep V tablet.
  • If you miss a scheduled dose of this medicine, contact your doctor immediately.

FAQs

Sovihep V tablet is a combination of two antiviral medicines, Sofosbuvir and Velpatasvir.

It works by removing the virus from the blood over time.

Reference

Feld, J. J., Jacobson, I. M.,Hézode, C., Asselah, T., Ruane, P., Gruener, N., Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610


Mangia, A., et al. (2020). Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5,552 patients from 12 cohorts. Liver International. Chandrashekhar, R., et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase III study with minimal monitoring in India. Hepatology International.


Uemura, Y., et al. (2021). Real‑world clinical application of 12-week sofosbuvir/velpatasvir  treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Journal of Clinical and Experimental Hepatology. (Open access). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680481/


Lee, S., et al. (2022). Efficacy and safety of sofosbuvir/velpatasvir ± ribavirin in genotype 3 compensated cirrhosis: a meta-analysis. World Journal of Hepatology, 14(6), 1248–1259. https://doi.org/10.4254/wjh.v14.i6.1248


Takehara, T., Sakamoto, N., Nishiguchi, S., et al. (2019). Sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase III trial. Journal of Gastroenterology, 54(1), 87–95. https://doi.org/10.1007/s00535-018-1503-x

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026